Personal Care Formulations
US-2024245591-A1 · Jul 25, 2024 · US
Use of L-Histidine and derivatives thereof
US9012483B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9012483-B2 |
| Application number | US-201214235128-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 24, 2012 |
| Priority date | Aug 2, 2011 |
| Publication date | Apr 21, 2015 |
| Grant date | Apr 21, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention discloses the use of L-Histidine to reduce Gadolinium accumulation into target organs, preventing its toxic effects, after administration of gadolinium based contrast agents. The invention thus, also disclose the use of L-Histidine to prevent the NSF syndrome in patients with renal functionality impairment. A kit of part is also disclosed by the use of which toxicity associated to free Gd3+, deriving from GDBCA, is prevented by oral administration of L-histidine before administration of the contrast agent. A method for the prevention of toxic metal accumulation which consists in the administration, preferably by the oral route, of L-Histidine is also disclosed. L-Histidine is preferably administered as a single oral dose comprised from 0.2-20 g.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of preventing Gadolinium (Gd 3+ ) accumulation in a patient's target organ after a GDBCA (Gadolinium Based Contrast Agent) administration comprising: administering L-Histidine or a derivative thereof before or simultaneous with administration of a GDBCA (Gadolinium Based Contrast Agent). 2. The method according to claim 1 , wherein said L-Histidine derivative is selected from the group consisting of: L-Histidine di-hydrochl…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9012483B2 cover?
- The present invention discloses the use of L-Histidine to reduce Gadolinium accumulation into target organs, preventing its toxic effects, after administration of gadolinium based contrast agents. The invention thus, also disclose the use of L-Histidine to prevent the NSF syndrome in patients with renal functionality impairment. A kit of part is also disclosed by the use of which toxicity assoc…
- Who is the assignee on this patent?
- Zsolt Baranyai, Brücher Ernö, Bussi Simona, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4172. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 21 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).